Cystic Fibrosis Clinical Trial
Official title:
Longitudinal Assessment of Fat Free Mass Index and Its Impact on Lung Health and Overall Health Metrics in Pediatric Patients With Cystic Fibrosis
The purpose of this study is to find out whether measurement of body composition has a prognostic value on clinical and overall outcome in pediatric patients with cystic fibrosis.
Cystic fibrosis (CF) is one of the most common life-threatening inherited disorders
affecting 1/35000 individuals in the US. In the past decades, the median predicted survival
of CF patients has increased significantly from 10-12 to over 37 years (1). One of the major
factors contributing to increased survival has been the understanding of the role of optimal
nutrition on overall health status of individuals with CF.
Forced expiratory volume in one second (FEV1) is currently the best predictor of pulmonary
health in CF, and malnutrition in a person of any age with CF has a negative impact on lung
function with a more rapid yearly decline in FEV1. Recent data from the Cystic Fibrosis
Foundation (CFF) patient registries in the United States and Canada were analyzed to
determine whether any association existed between pulmonary function as measured by FEV1 and
Body mass index (BMI) for age. BMI-for-age percentile values >50th percentile were
associated with well-preserved lung function and lower values of BMI were associated with
incrementally lower values of FEV1 (2). Thus, the CFF recommended that children with CF
between the ages of 2 and 20 years maintain a BMI a≥50th percentile for age and sex.
However, several publications have demonstrated that fat free muscle (FFM) wasting is
evident even in individuals with a BMI > 50th percentile, and it is unknown whether BMI
percentile adequately reflects changes in body composition in this group of patients;
therefore, BMI might not be the best marker indicating an optimal nutritional status.
Limitations of BMI as a marker of optimal Nutrition: fat mass versus muscle mass In
individuals with CF, BMI is used to assess appropriateness of weight to height for age and
sex. Since there is a strong association between BMI and overall health metrics, especially
lung health, the CFF recommends that children with CF maintain a BMI ≥50th percentile for
age and sex. However, an apparent loss of skeletal muscle may occur in CF patients who
retain their normal body weight, indicating that BMI does not provide any information about
body compartments and may fail to detect subtle alterations in body composition. Although
several epidemiologic studies showed that CF patients who maintain BMI> 50th percentile will
have improved lung functions and survival, recent data indicate that the preserved FFM
instead of BMI may have an impact on overall survival in CF (7). Because of the variability
in the levels of both fat mass and fat-free mass, and the many combinations of fat mass
index and FFM index associated with the same BMI, this weight-height index needs to be
carefully interpreted. Because high levels of BMI-for-age are associated with substantial
increases in fat mass, BMI is most useful as a measure of obesity. In chronic inflammatory
diseases, a change in regional fat distribution is observed with a shift to a more central
fat distribution. The latter is associated with an increase in low-grade chronic
inflammation, insulin resistance, and cardiovascular risk (8). Therefore, BMI is a good
index for assessment of obesity in otherwise normal children, but not adequate or sufficient
in the CF population.
In summary, some pediatric patients with CF may have a decreased Fat-free Mass Index (FFMI)
with a well preserved BMI of ≥50th percentile. Conversely, some patient might have a
BMI<50th percentile with normal FFMI associated with overall well-being. Current practice
forces CF patients to consume high fat and caloric nutrients to maintain a BMI >50th
percentiles incurring the costs of causing anxiety, stress, daily struggle in the family
with a potential increase in the pro-inflammatory state due to central fat accumulation. The
outcome of the proposed study will contribute to the understanding of the relationships
between BMI, muscle wasting and markers of health and wellbeing. If our study demonstrates
that a well maintained FFMI rather than the BMI correlates better with good health status in
CF, it may result in changes of current nutrition practice in CF at the national or even
international level.
;
Observational Model: Cohort, Time Perspective: Prospective
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT04696198 -
Thoracic Mobility in Cystic Fibrosis Care
|
N/A | |
| Completed |
NCT00803205 -
Study of Ataluren (PTC124™) in Cystic Fibrosis
|
Phase 3 | |
| Terminated |
NCT04921332 -
Bright Light Therapy for Depression Symptoms in Adults With Cystic Fibrosis (CF) and COPD
|
N/A | |
| Completed |
NCT03601637 -
Safety and Pharmacokinetic Study of Lumacaftor/Ivacaftor in Participants 1 to Less Than 2 Years of Age With Cystic Fibrosis, Homozygous for F508del
|
Phase 3 | |
| Terminated |
NCT02769637 -
Effect of Acid Blockade on Microbiota and Inflammation in Cystic Fibrosis (CF)
|
||
| Recruiting |
NCT06012084 -
The Development and Evaluation of iCF-PWR for Healthy Siblings of Individuals With Cystic Fibrosis
|
N/A | |
| Recruiting |
NCT06030206 -
Lung Transplant READY CF 2: A Multi-site RCT
|
N/A | |
| Recruiting |
NCT06032273 -
Lung Transplant READY CF 2: CARING CF Ancillary RCT
|
N/A | |
| Recruiting |
NCT06088485 -
The Effect of Bone Mineral Density in Patients With Adult Cystic Fibrosis
|
||
| Recruiting |
NCT05392855 -
Symptom Based Performance of Airway Clearance After Starting Highly Effective Modulators for Cystic Fibrosis (SPACE-CF)
|
N/A | |
| Recruiting |
NCT04039087 -
Sildenafil Exercise: Role of PDE5 Inhibition
|
Phase 2/Phase 3 | |
| Recruiting |
NCT04056702 -
Impact of Triple Combination CFTR Therapy on Sinus Disease.
|
||
| Completed |
NCT04058548 -
Clinical Utility of the 1-minute Sit to Stand Test as a Measure of Submaximal Exercise Tolerance in Patients With Cystic Fibrosis During Acute Pulmonary Exacerbation
|
N/A | |
| Completed |
NCT04038710 -
Clinical Outcomes of Triple Combination Therapy in Severe Cystic Fibrosis Disease.
|
||
| Completed |
NCT03637504 -
Feasibility of a Mobile Medication Plan Application in CF Patient Care
|
N/A | |
| Recruiting |
NCT03506061 -
Trikafta in Cystic Fibrosis Patients
|
Phase 2 | |
| Completed |
NCT03566550 -
Gut Imaging for Function & Transit in Cystic Fibrosis Study 1
|
||
| Recruiting |
NCT04828382 -
Prospective Study of Pregnancy in Women With Cystic Fibrosis
|
||
| Completed |
NCT04568980 -
Assessment of Contraceptive Safety and Effectiveness in Cystic Fibrosis
|
||
| Recruiting |
NCT04010253 -
Impact of Bronchial Drainage Technique by the Medical Device Simeox® on Respiratory Function and Symptoms in Adult Patients With Cystic Fibrosis
|
N/A |